CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [24]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Genome editing in rice and wheat using the CRISPR/Cas system
Shan, Q., Wang, Y., Li, J., & Gao, C. (2014) · Nature Protocols · doi:10.1038/nprot.2014.157 · Cited by 763
Research works printed but not linked: 1
- J. A. Doudna E. J. Sontheimer Eds. The Use of CRISPR/Cas9 ZFNs and TALENs in Generating Site-Specific Genome Alterations vol. 546 of Methods in Enzymology (Academic Press 2014) pp. xix–xx.
Cited by
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
“However, gene correction by HDR requires donor DNA, which is more difficult to deliver, and HDR appears to be particularly inefficient in certain quiescent cell types such as long-term repopulating HSCs (68, 69), although progress is being made (70).”
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Highly efficient therapeutic gene editing of human hematopoietic stem cells
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0401-y · Cited by 515
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319
Therapeutic base editing of human hematopoietic stem cells
Zeng, J., Wu, Y., Ren, C., Bonanno, J., Shen, A. H., Shea, D., Gehrke, J. M., Clement, K., Luk, K., Yao, Q., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0790-y · Cited by 283
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.010 · Cited by 245
A Review of Chronic Granulomatous Disease
Arnold, D. E., & Heimall, J. R. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0636-2 · Cited by 246
DNA Damage: From Threat to Treatment
Carusillo, A., & Mussolino, C. (2020) · Cells · doi:10.3390/cells9071665 · Cited by 241
Konstantakos, V., Nentidis, A., Krithara, A., & Paliouras, G. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac192 · Cited by 241
Mogensen, T. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03047 · Cited by 231
A New Class of Medicines through DNA Editing
Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229
NADPH oxidases and ROS signaling in the gastrointestinal tract
Aviello, G., & Knaus, U. G. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0021-8 · Cited by 225
Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I., & Six, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 199
Chronic Granulomatous Disease: a Comprehensive Review
Yu, H.-H., Yang, Y.-H., & Chiang, B.-L. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08800-x · Cited by 197
Gene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
“AATD, α-1 antitrypsin deficiency; AAV, adeno-associated virus; AAVS1, adeno-associated virus integration site 1; ACT, adoptive T-cell transfer; B2M, β-2 microglobulin; CAR, chimeric antigen receptor; CasRx, Ruminococcus flavefaciens XPD3002; CF, cystic fibrosis; CGD, chronic granulomatous disease; CjCas9, Campylobacte…”
BackgroundInfluentialGene correction for SCID-X1 in long-term hematopoietic stem cells
Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., Lee, C., Bao, G., Kildebeck, E. J., Punjya, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09614-y · Cited by 167
Self-citationTherapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 181
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Xiao, Q., Guo, D., & Chen, S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00069 · Cited by 179
Bak, R. O., Gomez-Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 176
“For example, among the genetic defects that affect the hematopoietic system, a number of diseases have been approached, including X-linked SCID [26], SCD [19,23], chronic granulomatous disease (CGD) [38,46], and X-linked hyper-IgM syndrome [18].”
BackgroundCRISPR-Cas9-mediated homology-directed repair for precise gene editing
Liao, H., Wu, J., VanDusen, N. J., Li, Y., & Zheng, Y. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102344 · Cited by 164
Carlson-Stevermer, J., Abdeen, A. A., Kohlenberg, L., Goedland, M., Molugu, K., Lou, M., & Saha, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01875-9 · Cited by 170
Chiesa, R., Wang, J., Blok, H.-J., Hazelaar, S., Neven, B., Moshous, D., Schulz, A., Hoenig, M., Hauck, F., Al Seraihy, A., et al. (2020) · Blood · doi:10.1182/blood.2020005590 · Cited by 162
Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations
Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., Kiem, H.-P., & Adair, J. E. (2019) · Nature Materials · doi:10.1038/s41563-019-0385-5 · Cited by 161
Rai, R., Romito, M., Rivers, E., Turchiano, G., Blattner, G., Vetharoy, W., Ladon, D., Andrieux, G., Zhang, F., Zinicola, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17626-2 · Cited by 133
Romero, Z., Lomova, A., Said, S., Miggelbrink, A., Kuo, C. Y., Campo-Fernandez, B., Hoban, M. D., Masiuk, K. E., Clark, D. N., Long, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.014 · Cited by 126
“As viral vectors, integrase-deficient lentiviral vectors (IDLVs) have been utilized for gene targeting of the IL2RG cDNA (exons 5–8) along with the GFP cassette into the IL2RG locus in murine and human HSPCs2 and for site-specific correction of the sickle mutation in HBB.3 Recombinant adeno-associated virus serotype 6…”
BackgroundCooperative CAR targeting to selectively eliminate AML and minimize escape
Haubner, S., Mansilla‐Soto, J., Nataraj, S. E., Kogel, F., Chang, Q., de Stanchina, E., Lopez, M. A., Ng, M. R., Fraser, K. A., Subklewe, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.010 · Cited by 135
Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122
“…donor DNA delivered as single-stranded oligonucleotides (ssODNs), integration-defective lentiviral vectors (ÍDLVs), or by recombinant adeno-associated virus serotype 6 (rAAV6) vectors (Dever et al., 2016; DeWitt et al., 2016; De Ravin et al., 2017; Wang et al., 2015; Hoban et al., 2016).”
BackgroundCRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors
Bak, R. O., & Porteus, M. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.064 · Cited by 124
“…virus (AAV), can transduce both dividing and non-dividing cells and have recently been effectively used as donor vectors for HR both in vitro and in vivo (Sather et al., 2015, Wang et al., 2015, DeWitt et al., 2016, Yang et al., 2016, Yin et al., 2016, Dever et al., 2016, De Ravin et al., 2017).”
MethodCRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects
Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S., Tse, H.-F., & Lian, Q. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.09.009 · Cited by 114
Lessard, S., Francioli, L., Alfoldi, J., Tardif, J.-C., Ellinor, P. T., MacArthur, D. G., Lettre, G., Orkin, S. H., & Canver, M. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714640114 · Cited by 112
CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments
Laurent, M., Geoffroy, M., Pavani, G., & Guiraud, S. (2024) · Cells · doi:10.3390/cells13100800 · Cited by 150
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
Naldini, L. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809958 · Cited by 110
“…even the most primitive cells into replication while preserving their engraftment capacity and by tailoring the gene editing machinery to avoid triggering innate immune cellular responses (Genovese et al, 2014; Wang et al, 2015; De Ravin et al, 2016a, 2017; Dever et al, 2016; Schiroli et al, 2017).”
BackgroundEx vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 130
Petrillo, C., Thorne, L. G., Unali, G., Schiroli, G., Giordano, A. M. S., Piras, F., Cuccovillo, I., Petit, S. J., Ahsan, F., Noursadeghi, M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.008 · Cited by 106
CRISPR-based therapeutics: current challenges and future applications
Modell, A. E., Lim, D., Nguyen, T. M., Sreekanth, V., & Choudhary, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.012 · Cited by 104
CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection
Gong, S., Zhang, S., Lü, F., Pan, W., Li, N., & Tang, B. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02533 · Cited by 105
Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease
Rider, N. L., Jameson, M. B., & Creech, C. B. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy008 · Cited by 115
“CRISPR-Cas9 genome-editing tool [51], to explore additional immunologic manifestations of NADPH oxidase defects and”
MethodEngineering Precision Medicine
Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 103
Self-citationPattabhi, S., Lotti, S. N., Berger, M. P., Singh, S., Lux, C. T., Jacoby, K., Lee, C., Negre, O., Scharenberg, A. M., & Rawlings, D. J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.05.025 · Cited by 91
“This overall decline in engraftment of HDR-edited cells is consistent with multiple previous reports using each of these donor template delivery approaches.(20,22,29,31,32,36,37) Notably, however, despite the loss of HDR-edited cells in both settings, the proportion of HDR-edited cells remained 6-fold higher (4.”
ResultX-Linked Agammaglobulinaemia: Outcomes in the modern era
Shillitoe, B. M. J., & Gennery, A. R. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.07.008 · Cited by 98
Shin, J. J., Schröder, M., Caiado, F., Wyman, S. K., Bray, N., Bordi, M., DeWitt, M. A., Vu, J. T., Kim, W., Hockemeyer, D. F., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108093 · Cited by 95
Cromer, M. K., Camarena, J., Martin, R. M., Lesch, B. J., Vakulskas, C. A., Bode, N. M., Kurgan, G., Collingwood, M. A., Rettig, G. R., Behlke, M. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01284-y · Cited by 82
Liu, Q., He, D., & Xie, L. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007480 · Cited by 81
Allen, D. G., Rosenberg, M., & Hendel, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617910 · Cited by 95
Precise genome-editing in human diseases: mechanisms, strategies and applications
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01750-2 · Cited by 106
“In another case of successful therapeutic gene editing, Malech et al. 399,400 achieved insertion of the wild-type CYBB gene into the AAVS1 locus or corrected the mutant CYBB gene in CD34 + HSPCs obtained from patients with the X-linked chronic granulomatous disease (X-CGD) using HDR strategies.”
MethodEvolving Gene Therapy in Primary Immunodeficiency
Thrasher, A. J., & Williams, D. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.018 · Cited by 82
Custom CRISPR–Cas9 PAM variants via scalable engineering and machine learning
Silverstein, R. A., Kim, N., Kroell, A.-S., Walton, R. T., Delano, J., Butcher, R. M., Pacesa, M., Smith, B. K., Christie, K. A., Ha, L. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09021-y · Cited by 73
“Epstein–Barr virus-transformed B cell lines (BCLs) were established from a patient with chronic granulomatous disease harbouring the CYBB T362I mutation as previously described 55,91 (the patient was consented via the US National Institutes of Health (NIH) protocol 05-I-0213).”
Recent advances in CRISPR/Cas9-mediated knock-ins in mammalian cells
Banan, M. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.11.010 · Cited by 85
De Ravin, S. S., Brault, J., Meis, R. J., Liu, S., Li, L., Pavel-Dinu, M., Lazzarotto, C. R., Liu, T., Koontz, S. M., Choi, U., et al. (2021) · Blood · doi:10.1182/blood.2020008503 · Cited by 72
Self-citationGenetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.014 · Cited by 70
Cavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 80
“21 Recent work by Naldini ’ s team highlighted the superiority of the IDLV platform when serving as a carrier of donor template for HDR-mediated gene KI in HSPCs.”
InfluentialXenotransplantation: back to the future?
Meier, R. P. H., Müller, Y. D., Balaphas, A., Morel, P., Pascual, M. A., Seebach, J. D., & Bühler, L. H. (2018) · Transplant International · doi:10.1111/tri.13104 · Cited by 80
Roulis, E. V., Hyland, C. A., Flower, R. L., Gassner, C., Jung, H. H., & Frey, B. M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2166 · Cited by 71
CRISPR-Cas9 system: A genome-editing tool with endless possibilities
Tyagi, S., Kumar, R., Das, A., Won, S. Y., & Shukla, P. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.05.008 · Cited by 78
Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy
Wang, L., Zheng, W., Liu, S., Li, B., & Jiang, X. (2019) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 64
Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases
Papasavva, P. L., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00392-3 · Cited by 76
“[46] for X-linked chronic granulomatous disease (Tables 1 and 2, yellow), who employed electroporation of RNP and a single-stranded oligodeoxynucleotide (ssODN) donor to achieve up to 21% HDR in all alleles.”
BackgroundOxidants in Physiological Processes
Knaus, U. G. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_380 · Cited by 74
Dever, D. P., & Porteus, M. H. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000385 · Cited by 62
Gene therapy for primary immunodeficiency
Booth, C., Romano, R., Roncarolo, M. G., & Thrasher, A. J. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz170 · Cited by 64
Rose, J. C., Popp, N. A., Richardson, C. D., Stephany, J. J., Mathieu, J., Wei, C. T., Corn, J. E., Maly, D. J., & Fowler, D. M. (2020) · Nature Communications · doi:10.1038/s41467-020-16542-9 · Cited by 58
Kotagama, O. W., Jayasinghe, C. D., & Abeysinghe, T. (2019) · BioMed Research International · doi:10.1155/2019/1369682 · Cited by 48
CRISPR/Cas9 cleavage efficiency regression through boosting algorithms and Markov sequence profiling
Peng, H., Zheng, Y., Blumenstein, M., Tao, D., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty298 · Cited by 57
“We introduce a two-step averaging method (TSAM) granulomatous disease (Yu et al. , 2017; De Ravin et al. , 2017) The highly efficient sgRNAs recommended by our method can well match with those sgRNAs which had been validated by wet lab experiments and domain experts .”
MethodCRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 63
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 71
“Moreover, the correction of the CYBB gene in HSPCs is one of the potential therapeutic strategies for X-linked chronic granulomatous disease (X-CGD)[64].”
BackgroundMyeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment
Arai, Y., Choi, U., Corsino, C. I., Koontz, S. M., Tajima, M., Sweeney, C. L., Black, M. A., Feldman, S. A., Dinauer, M. C., & Malech, H. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.003 · Cited by 56
Self-citationTherapeutic applications of CRISPR/Cas9 system in gene therapy
Mollanoori, H., & Teimourian, S. (2018) · Biotechnology Letters · doi:10.1007/s10529-018-2555-y · Cited by 54
“Patient-derived iPSC from X-linked chronic granulomatous disease (X-CGD) patients containing point mutations in the CYBB gene repaired by CRISPR/ Cas9-mediated HDR approach and then transplant to the patients (De Ravin et al. 2017).”
BackgroundHigh-level correction of the sickle mutation is amplified in vivo during erythroid differentiation
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Campo-Fernández, B., Said, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104374 · Cited by 55
Vavassori, V., Mercuri, E., Marcovecchio, G. E., Castiello, M. C., Schiroli, G., Albano, L., Margulies, C. M., Buquicchio, F. A., Fontana, E., Beretta, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013545 · Cited by 53
“Over the last years, targeted gene editing has emerged as potential therapeutic option for several genetic diseases (Genovese et al, 2014; Dever et al, 2016; De Ravin et al, 2017; Schiroli et al, 2017).”
BackgroundRecent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells
Lotfi, M., Rad, D. M., Mashhadi, S., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., Farrokhi, S., Hashemi, M., Lotfi, M., Warkiani, M. E., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10585-3 · Cited by 65
“…as the most popular gene editing approach to study cystic fibrosis [6, 7], sickle cell disease (SCD) [8, 9], Huntington’s chorea disorder [10, 11], Duchenne muscular dystrophy [12–14], chronic granulomatous disease [15, 16] retinitis pigmentosa [17] hemophilia [18, 19], and thalassemia [20–22].”
BackgroundGutiérrez-Guerrero, A., Abrey-Recalde, M. J., Mangeot, P. E., Costa, C., Bernadin, O., Perian, S., Fusil, F., Froment, G., Martinez-Turtos, A., Krug, A., et al. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.604371 · Cited by 60
Strategies for the CRISPR-Based Therapeutics
Li, B., Niu, Y., Ji, W., & Dong, Y. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.006 · Cited by 50
“Moreover, production of functional mature human myeloid and lymphoid cells lasts up to 5 months when corrected X-CGD HSPCs are transplanted into mouse models [62].”
BackgroundSweeney, C. L., Pavel-Dinu, M., Choi, U., Brault, J., Liu, T., Koontz, S. M., Li, L., Theobald, N., Lee, J., Bello, E. A., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00251-z · Cited by 52
Self-citationGene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 57
Recent advances in genome editing of stem cells for drug discovery and therapeutic application
Lee, J., Bayarsaikhan, D., Bayarsaikhan, G., Kim, J.-S., Schwarzbach, E., & Lee, B. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107501 · Cited by 47
Self-citationCRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
Lone, B. A., Karna, S. K. L., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2018) · Genetics Research International · doi:10.1155/2018/3797214 · Cited by 60
“CRISPR editing approaches have been applied for the correction of common β-hemoglobinopathies, including sickle cell disease (SCD) [132, 133] and β-thalassemia disorders [134] as well as an immunodeficient disorder (chronic granulomatous disease) caused by defect in NADPH oxidase 2 (NOX2) protein [135].”
BackgroundHomology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing
Zhang, X., Li, T., Ou, J., Huang, J., & Liang, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00838-7 · Cited by 51
“By delivering two AAV donors together with CRISPR-Cas nuclease, it is feasible to insert 5,700-nt DNA in HSPCs and T cells (Bak and Porteus, 2017).”
BackgroundInfluentialCRISPR/Cas9: the Jedi against the dark empire of diseases
Khan, S., Mahmood, M. S., Rahman, S. U., Zafar, H., Khan, S. H., khan, Z., & Ahmad, A. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0425-5 · Cited by 57
“Recently, CRISPR/Cas9 was used by a team of scientist who were successful in correcting the mutation in the CYBB gene of HPSCs from patients suffering from X-CGD [117].”
Therapy Development by Genome Editing of Hematopoietic Stem Cells
Koniali, L., Lederer, C. W., & Kleanthous, M. (2021) · Cells · doi:10.3390/cells10061492 · Cited by 54
“In further studies employing CRISPR/Cas9 in combination with ssODN, the same group initially reported 12–31% targeted correction of the CYBB 676C>T point mutation in X-CGD patient-derived HSCs [167], before transient inhibition of p53-mediated apoptosis and transplantation into immunodeficient mice enabled up to 80% t…”
BackgroundCancer Nanomedicines in an Evolving Oncology Landscape
Guo, P., Huang, J., & Moses, M. A. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.001 · Cited by 43
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
“The current approach toward HSC gene therapy uses electroporation of CRISPR-Cas mRNA or RNPs to edit HSC genomes.(40) If homology-directed repair is required, the template is simultaneously electroporated or transduced by viral vectors.”
Gardner, C. L., Pavel-Dinu, M., Dobbs, K., Bosticardo, M., Reardon, P. K., Lack, J., Ravin, S. S. D., Le, K., Bello, E. A., Pala, F., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-00989-6 · Cited by 43
Self-citationCosenza, L. C., Gasparello, J., Romanini, N., Zurlo, M., Zuccato, C., Gambari, R., & Finotti, A. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.025 · Cited by 47
“For instance, CRISPR-Cas9 has been employed in cystic fibrosis,(38,39) SCD,(40,41) Huntington’s chorea disorder,(42,43) Duchenne muscular dystrophy,(44,45) hemophilia,(46,47) and chronic granulomatous disease.(48,49)”
MethodChemical Tools for Targeted Amplification of Reactive Oxygen Species in Neutrophils
Reshetnikov, V., Hahn, J., Maueröder, C., Czegley, C., Munoz, L. E., i, M. H., Hoffmann, M. H., & Mokhir, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01827 · Cited by 42
“Particularly, gene therapy using lentiviral vectors enabling specific expression in myeloid cells (22) and approaches employing the clustered regularly interspaced short palindromic repeats/Cas9 system (23) have obtained promising results.”
BackgroundLee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 40
Sürün, D., Schwäble, J., Tomasovic, A., Ehling, R., Stein, S., Kurrle, N., von Melchner, H., & Schnütgen, F. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2017.11.001 · Cited by 39
“Next,we cloned sgRNAs targeting differentCYBBmutations (Table S1) into pLentiCRISPRv2and infectedFACS-sorted, BFP+XCGDcellswith corresponding LC-sgCYBB IDLVs.”
ResultTherapeutic gene editing in haematological disorders with CRISPR /Cas9
Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019) · British Journal of Haematology · doi:10.1111/bjh.15851 · Cited by 43
“(Holkers et al, 2014; Dever et al, 2016; De Ravin et al, 2017; Eyquem et al, 2017).”
Targeted Gene Delivery: Where to Land
Pavani, G., & Amendola, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.609650 · Cited by 55
Gene therapy and genome editing for primary immunodeficiency diseases
Zhang, Z., Thrasher, A. J., & Zhang, F. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.007 · Cited by 40
“A single-stranded DNA oligonucleotide (ssODN) donor has been shown as a simple and effective approach in genome editing for correction of single-nucleotide mutation in HSPCs.(104,105) Integration defective lentiviral vector (IDLV), that allow incorporation of a large DNA template, has been used for ZFN-mediated genome…”
BackgroundMethodResultInfluentialDaniel-Moreno, A., Lamsfus‐Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0510-8 · Cited by 49
Brendel, C., Río, P., & Verhoeyen, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113711 · Cited by 41
Current advances of CRISPR-Cas technology in cell therapy
Qiu, H.-Y., Ji, R.-J., & Zhang, Y. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100067 · Cited by 41
Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy
Azhagiri, M. K. K., Babu, P., Venkatesan, V., & Thangavel, S. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02565-6 · Cited by 35
“CRISPR/Cas9 RNP and ssODNmediated correction of C676T point mutation with an in vitro efficiency of 20% and in vivo efficiency of 13% was achieved [29].”
BackgroundStem cell transplantation for Huntington’s diseases
Choi, K., Choi, Y., & Hong, S. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.017 · Cited by 35
Capo, V., Castiello, M. C., Fontana, E., Penna, S., Bosticardo, M., Draghici, E., Poliani, P. L., Sergi, L. S., Rigoni, R., Cassani, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.015 · Cited by 33
Therapeutic gene editing of T cells to correct CTLA-4 insufficiency
Fox, T. A., Houghton, B. C., Petersone, L., Waters, E., Edner, N. M., McKenna, A. J., Preham, O., Hinze, C., Williams, C., Albuquerque, A. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5811 · Cited by 36
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Lionakis, M. S. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000593 · Cited by 33
“All rights rese the infection, because opsonization may be suboptimal in the CNS. Invasive infections by inhaled molds Development of invasive aspergillosis in the absence of iatrogenic immunosuppression should raise suspicion for underlying congenital neutropenia syndromes, LAD-1, or CGD; the latter is associated wit…”
BackgroundInfluentialProgress in treating chronic granulomatous disease
Gennery, A. R. (2020) · British Journal of Haematology · doi:10.1111/bjh.16939 · Cited by 34
Metadata
- Authors
- De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., Sweeney, C., Kardava, L., Moir, S., Viley, A., Natarajan, P., Su, L., Kuhns, D., Zarember, K. A., Peshwa, M. V., & Malech, H. L.
- Affiliations
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- MaxCyte (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- National Institutes of Health (US)
- Corresponding author
- Li, Linhong
- Malech, Harry L.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-01-11
- Volume
- 9
- Issue
- 372
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2577713652
- Semantic Scholar
- 531bffc692cccebccbf571ed886fd2766c50f091
- Cited by
- 258
- References
- 32
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 23 · 2023: 19 · 2022: 23 · 2021: 36 · 2020: 39 · 2019: 35 · 2018: 26 · 2017: 25
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program of NIAID
- NIH (Z01-A1-00644, Z01-A1-00988)
- Maryland Stem Cell Research Fund (#2015-MSCRFP-1752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9 genome editing, X-linked chronic granulomatous disease, hematopoietic stem cells, CYBB gene, gene correction, engraftment
- MeSH terms
- NADPH Oxidase 2, Animals, Cell Differentiation, DNA Repair, Female, Granulomatous Disease, Chronic, Hematopoietic Stem Cells, Humans, Mutation, Oligonucleotides, Genetic Therapy, Mutagenesis, Mice, SCID, Mice, Inbred NOD, Antigens, CD34, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.